Harnessing regulatory T cells for therapeutic purposes.

Abstract

Lai and colleagues demonstrate that pretreatment with N,N-dimethylsphingosine (DMS), a naturally occurring sphingosine derivative, provides renoprotection in ischemia/reperfusion injury. This DMS-induced renoprotection was abolished by the administration of agents that suppress regulatory T cells (Tregs) or by anti-CTLA-4 or anti-CD45 monoclonal antibodies, suggesting that Tregs played a critical role. The finding that Tregs are recruited to the kidney via DMS points to the exciting potential of new approaches to harnessing Tregs for therapeutic purposes.

• Authors: Laurence Chan
• Journal: Kidney international (Kidney Int) Vol. 81 Issue 10 Pg. 935-936 (May 2012) ISSN: 1523-1755 [Electronic] United States
• PMID: 22543901 (Publication Type: Journal Article, Comment)

Chemical References

• Immunologic Factors
• N,N-dimethylsphingosine
• Sphingosine

Topics

• Acute Kidney Injury (prevention & control)
• Animals
• Chemotaxis, Leukocyte (drug effects)
• Immunologic Factors (pharmacology)
• Ischemia (drug therapy)
• Kidney (drug effects)
• Male
• Reperfusion Injury (prevention & control)
• Sphingosine (analogs & derivatives, pharmacology)
• T-Lymphocytes, Regulatory (drug effects)